Progress the pre-clinical development of DNDi-0690, a selected nitroimidazole for the treatment of visceral leishmaniasis and possibly cutaneous leishmaniasis.
current phase of drug development
updated 29 Feb 2020
Nitroimidazole derivatives hold great potential to address unmet needs in tuberculosis (TB) therapy. As well as developing a clinical candidate for TB, the TB Alliance instituted a backup programme to maximize the potential of this class of anti-bacterial agents.Through a contractual agreement with TB Alliance, DNDi gained access to a library of around 70 nitroimidazoles which were then tested for potential anti-leishmanial activity.
Following the termination of the VL-2098 project in early 2015, two lead compounds from the nitroimidazooxazine back-up programme were progressed. One of these, DNDI-0690, showed good to excellent activity in vitro against both visceral leishmaniasis and cutaneous leishmaniasis causing strains of Leishmania and was nominated as a preclinical candidate in September 2015.
DNDI-0690 and other potential lead compounds for visceral leishmaniasis were profiled in vitro against CL-causing strains of Leishmania at the London School of Hygiene & Tropical Medicine and the Walter Reed Army Institute of Research.
Get our latest news, personal stories, research articles, and job opportunities.